BioCryst Introduces Orladeyo in Ireland for Regular Prevention of HAE Recurrent Attacks in Those Aged 12 and Up
BioCryst Pharmaceuticals, Inc., a leading biotech firm, revealed that Ireland’s Health Services Executive (HSE) has endorsed Orladeyo (berotralstat) for the regular prevention of repeated hereditary angioedema (HAE) attacks in suitable patients aged 12 and above. This endorsement enables Irish HAE […]